Analysts Set Expectations for Ardelyx FY2025 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Ardelyx in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal expects that the biopharmaceutical company will earn ($0.13) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. Ardelyx had a negative net margin of 11.73% and a negative return on equity of 24.87%. The business had revenue of $116.13 million during the quarter, compared to analysts’ expectations of $111.16 million.

ARDX has been the topic of a number of other reports. HC Wainwright reaffirmed a “neutral” rating and set a $5.50 target price on shares of Ardelyx in a research report on Friday, February 21st. BTIG Research started coverage on Ardelyx in a report on Tuesday. They set a “buy” rating and a $14.00 price target for the company. Piper Sandler boosted their price target on Ardelyx from $7.00 to $8.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Raymond James reiterated a “strong-buy” rating and issued a $13.00 target price (down from $15.00) on shares of Ardelyx in a research note on Friday, February 21st. Finally, Jefferies Financial Group dropped their price target on shares of Ardelyx from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, January 2nd. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.44.

Ardelyx Stock Performance

Shares of NASDAQ ARDX opened at $5.44 on Thursday. Ardelyx has a 1 year low of $4.32 and a 1 year high of $9.79. The firm has a market cap of $1.30 billion, a P/E ratio of -34.00 and a beta of 0.85. The stock has a fifty day moving average price of $5.37 and a two-hundred day moving average price of $5.60. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.31 and a current ratio of 4.58.

Institutional Investors Weigh In On Ardelyx

Several large investors have recently made changes to their positions in ARDX. Janus Henderson Group PLC boosted its stake in Ardelyx by 13.3% in the 4th quarter. Janus Henderson Group PLC now owns 24,387,941 shares of the biopharmaceutical company’s stock worth $123,587,000 after purchasing an additional 2,858,061 shares during the period. Two Seas Capital LP bought a new stake in shares of Ardelyx in the 4th quarter valued at about $9,407,000. Rock Springs Capital Management LP bought a new position in Ardelyx during the fourth quarter worth about $7,421,000. D. E. Shaw & Co. Inc. lifted its holdings in Ardelyx by 9,499.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,468,668 shares of the biopharmaceutical company’s stock valued at $7,446,000 after purchasing an additional 1,453,369 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Ardelyx in the 4th quarter valued at about $6,762,000. Institutional investors own 58.92% of the company’s stock.

Insider Activity at Ardelyx

In related news, CEO Michael Raab sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $5.26, for a total value of $131,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,150,385 shares in the company, valued at approximately $6,051,025.10. The trade was a 2.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David M. Mott bought 213,300 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were acquired at an average cost of $4.67 per share, with a total value of $996,111.00. Following the completion of the purchase, the director now owns 1,638,765 shares in the company, valued at $7,653,032.55. This represents a 14.96 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 490,029 shares of company stock valued at $2,377,766 and have sold 141,408 shares valued at $761,963. 5.90% of the stock is owned by insiders.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.